These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 18560996)

  • 1. Dynamic dissolution testing to establish in vitro/in vivo correlations for montelukast sodium, a poorly soluble drug.
    Okumu A; DiMaso M; Löbenberg R
    Pharm Res; 2008 Dec; 25(12):2778-85. PubMed ID: 18560996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biorelevant dissolution media as a predictive tool for glyburide a class II drug.
    Wei H; Löbenberg R
    Eur J Pharm Sci; 2006 Sep; 29(1):45-52. PubMed ID: 16815694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products.
    Okumu A; DiMaso M; Löbenberg R
    Eur J Pharm Biopharm; 2009 May; 72(1):91-8. PubMed ID: 19056493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simulation of in vitro dissolution behavior using DDDPlus™.
    Almukainzi M; Okumu A; Wei H; Löbenberg R
    AAPS PharmSciTech; 2015 Feb; 16(1):217-21. PubMed ID: 25409918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
    Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vivo Predictive Dissolution Testing of Montelukast Sodium Formulations Administered with Drinks and Soft Foods to Infants.
    Martir J; Flanagan T; Mann J; Fotaki N
    AAPS PharmSciTech; 2020 Oct; 21(7):282. PubMed ID: 33051713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissolution rate and apparent solubility of poorly soluble drugs in biorelevant dissolution media.
    Fagerberg JH; Tsinman O; Sun N; Tsinman K; Avdeef A; Bergström CA
    Mol Pharm; 2010 Oct; 7(5):1419-30. PubMed ID: 20507160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toward Biopredictive Dissolution for Enteric Coated Dosage Forms.
    Al-Gousous J; Amidon GL; Langguth P
    Mol Pharm; 2016 Jun; 13(6):1927-36. PubMed ID: 27139040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the design of fasted state simulating intestinal fluids: FaSSIF-V3.
    Fuchs A; Leigh M; Kloefer B; Dressman JB
    Eur J Pharm Biopharm; 2015 Aug; 94():229-40. PubMed ID: 26032292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance Evaluation of Montelukast Pediatric Formulations: Part I-Age-Related In Vitro Conditions.
    Guimarães M; Somville P; Vertzoni M; Fotaki N
    AAPS J; 2022 Jan; 24(1):26. PubMed ID: 35013835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One and Two-Step In Vitro-In Vivo Correlations Based on USP IV Dynamic Dissolution Applied to Four Sodium Montelukast Products.
    Prieto-Escolar M; Torrado JJ; Álvarez C; Ruiz-Picazo A; Simón-Vázquez M; Govantes C; Frias J; García-Arieta A; Gonzalez-Alvarez I; Bermejo M
    Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34064700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissolution Profile of Mefenamic Acid Solid Dosage Forms in Two Compendial and Biorelevant (FaSSIF) Media.
    Nurhikmah W; Sumirtapura YC; Pamudji JS
    Sci Pharm; 2016; 84(1):181-90. PubMed ID: 27110508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior of glibenclamide.
    Löbenberg R; Krämer J; Shah VP; Amidon GL; Dressman JB
    Pharm Res; 2000 Apr; 17(4):439-44. PubMed ID: 10870988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integration of Biorelevant Pediatric Dissolution Methodology into PBPK Modeling to Predict In Vivo Performance and Bioequivalence of Generic Drugs in Pediatric Populations: a Carbamazepine Case Study.
    Pawar G; Wu F; Zhao L; Fang L; Burckart GJ; Feng K; Mousa YM; Al Shoyaib A; Jones MC; Batchelor HK
    AAPS J; 2023 Jun; 25(4):67. PubMed ID: 37386339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
    Fei Y; Kostewicz ES; Sheu MT; Dressman JB
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiologically based pharmacokinetic model outputs depend on dissolution data and their input: Case examples glibenclamide and dipyridamole.
    Klumpp L; Dressman J
    Eur J Pharm Sci; 2020 Aug; 151():105380. PubMed ID: 32442630
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Silva TMD; Honorio TDS; Chaves MHDC; Duque MD; Cabral LM; Patricio BFC; Rocha HVA
    Drug Dev Ind Pharm; 2021 Aug; 47(8):1342-1352. PubMed ID: 34622730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hierarchical Mass Transfer Analysis of Drug Particle Dissolution, Highlighting the Hydrodynamics, pH, Particle Size, and Buffer Effects for the Dissolution of Ionizable and Nonionizable Drugs in a Compendial Dissolution Vessel.
    Salehi N; Al-Gousous J; Mudie DM; Amidon GL; Ziff RM; Amidon GE
    Mol Pharm; 2020 Oct; 17(10):3870-3884. PubMed ID: 32886520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral Absorption from Surfactant-Based Drug Formulations: The Impact of Molecularly Dissolved Drug on Bioavailability.
    Holzem FL; Parrott N; Petrig Schaffland J; Brandl M; Bauer-Brandl A; Stillhart C
    J Pharm Sci; 2024 Oct; 113(10):3054-3064. PubMed ID: 39059554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro dissolution models for the prediction of in vivo performance of an oral mesoporous silica formulation.
    McCarthy CA; Faisal W; O'Shea JP; Murphy C; Ahern RJ; Ryan KB; Griffin BT; Crean AM
    J Control Release; 2017 Mar; 250():86-95. PubMed ID: 28132935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.